Chemical Business Newsbase articles from October 2008

Chemical Business Newsbase archives from October 2008

FDA approves Toviaz, a new drug to treat overactive bladder.
October 31, 2008... On 31 Oct 2008, the US Food and Drug Administration has approved a new drug to help patients suffering from overactive bladder (OAB). Toviaz (fesoterodine fumarate) works by relaxing the smooth muscle tissue of the bladder, thus reducing the...

NMDC: Results for 2Q 2008-2009. [2 tables in original article].
October 31, 2008... NMDC Ltd has reported a net profit of Rup 9449.3 M on net sales/income from operations of Rup 16.1732 bn for 2Q ended Sep 2008 (net profit of Rup 6400.2 M on net sales/income from operations of Rup 11.1154 bn in 2Q ended Sep 2007). The...

Strides Arcolab readies for oncology drive: To roll out 32 of its own anti-cancer products soon.
October 31, 2008... Strides Arcolab plans to introduce 32 of its own anti-cancer drugs by May 2009 under the label of Grandix, the Chennai-based firm acquired by Strides Arcolab in 2007 for Rup 1 bn. The market for anti-cancer drugs in India is estimated at...

DSCL posts Rup 71.2 M PAT in 2Q 2008-2009.
October 31, 2008... DCM Shriram Consolidated Ltd (DSCL) has reported a profit-after-tax (PAT) of Rup 71.2 M for 2Q ended Sep 2008 (loss of Rup 191.6 M in 2Q ended Sep 2007). The operating profit was higher by 150% at Rup 760.5 M for 2Q 2008-2009 (operating...

Dabur net profit rises 18.1% for 2Q 2008-2009.
October 31, 2008... Dabur India (Dabur) has reported an 18.1% higher net profit at Rup 1069.6 M for 2Q ended Sep 2008 (net profit of Rup 905.5 M in 2Q ended Sep 2007). During 1H ended Sep 2008, the company recorded a 21% increase in net profit at Rup 1771.1 M in...

KSE Ltd: results for 2Q 2008-2009. [2 tables in original article].
October 31, 2008... KSE Ltd has incurred a net loss of Rup 27.425 M on net sales of Rup 902 M for 2Q ended Sep 2008 (net profit of Rup 5.55 M on net sales of Rup 703.035 M in 2Q ended Sep 2007). The company derived revenues of Rup 710.29 M from its animal feed...

Nagarjuna Fertilizers: Results for 2Q 2008-2009. [1 table in original article].
October 31, 2008... Fertilizer firm Nagarjuna Fertilizers and Chemicals Ltd has registered a net profit of Rup 81.54 M on net sales/income from operations of Rup 8558.672 M for 2Q ended Sep 2008 (net profit of Rup 86.619 M on net sales/income from operations of...

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 Sep 2008 to 30 Sep 2008. [6 tables in original article].
October 31, 2008... The European Commission has taken decisions on marketing authorization of medical products from 1 Sep 2008 to 30 Sep 2008. The Following six tables are included: issuing of a marketing authorization (Article 13 of Regulation (EC) No...

Chevron Phillips Chemical to relocate its Orange Technology Center.
October 31, 2008... On 31 Oct 2008, Chevron Phillips Chemical Co LLC announced plans to relocate services provided by the company's Orange Technology Center to its Plastics Technology Center in Bartlesville, Oklahoma. The move will combine the team providing...

New and generic drug approvals: Skelaxin Tablet, King Pharms.
October 31, 2008... On 31 Oct 2008, the US Food and Drug Administration announced approval of NDA 013217 (package change) for Skelaxin Tablet. The product contains metaxalone at 400mg or 800mg, is manufactured by King Pharms, and is prescription only. There are...

New and generic drug approvals: Theophylline in Dextrose 5% Injection in Plastic Container, Hospira. [7 tables in original article].
October 31, 2008... On 31 Oct 2008, the US Food and Drug Administration announced approval of NDA 019211 (package change) for Theophylline in Dextrose 5% Injection in Plastic Container. The product contains theophylline (in 5% dextrose) at 4mg/ml, 40mg/100ml,...

New and generic drug approvals: Requip XL Extended Release Tablet, SmithKline Beecham.
October 31, 2008... On 31 Oct 2008, the US Food and Drug Administration announced approval of NDA 022008 (new dosage regimen) for Requip XL Extended Release Tablet. The product contains ropinirole hydrochloride at 2mg, 3mg, 4mg, or 8mg (eq base), is manufactured...

New and generic drug approvals: Treanda Injection, Cephalon.
October 31, 2008... On 31 Oct 2008, the US Food and Drug Administration announced approval of NDA 022303 for Treanda Injection. The product contains bendamustine hydrochloride at 100mg, is manufactured by Cephalon, and is prescription only. There are no...

UC RusAl wants to create State reserves of the metals.
October 31, 2008... UC RusAl (Russian/Swiss JV on alumina and aluminium production) expects that the financial crisis and a fall in non- ferrous metal output will lead to 1.2 M workers in the industry being laid off. The Russian budget will lack Roubles 200 bn...

Healthy growth for fatty alcohols in Europe.
October 31, 2008... The European market for fatty alcohols is growing steadily in terms of both volume and value. Revenues in 2008 are estimated at EUR 1.011 bn and this is forecast to rise to EUR 1.670 bn by 2015, representing an average annual growth rate of...

Brazil's Petrobras granted right to Texas refinery in arbitration.
October 31, 2008... Brazilian oil company Petroleo Brasileiro (Petrobras) announced on 31 Oct 2008 that the International Centre for Dispute Resolution has approved its right to acquire Transcor Astra Group's 50% stake in Pasadena Refining. The price of the deal...

Brazil Natura restructuring leads to job cuts - report.
October 31, 2008... Brazilian cosmetics company Natura is starting to reduce its workforce, eight months after announcing an aggressive restructuring plan, local daily O Estado de S Paulo reported. So far, Natura has eliminated 200 jobs and dismissed 100...

Brazil miner Vale cuts production but maintains 2009 investment.
October 31, 2008... Brazil's mining giant Companhia Vale do Rio Doce (Vale) will reduce production of iron ore, manganese, ferroalloy, nickel and aluminium as a result of the slowdown caused by the global financial crisis. In a statement, Vale said it already...

Brazil's Vale output cut means $2.2 bn less exports - AEB.
October 31, 2008... The cut in production announced earlier on 31 Oct 2008 by Brazilian mining company Vale will represent a $2.2 bn 12-month drop in export revenue and increases the chance a Brazilian trade deficit, Jose Augusto de Castro the president of the...

Marshall Edwards' Phenoxodiol and Novogen's NV-128 display divergent mechanisms of action but potent synergistic anti-cancer activity when used in combination.
October 31, 2008... Pre-clinical studies presented at the 9th International Conference on Membrane Redox Systems in Wellington New Zealand duirng the last week of Oct 2008 demonstrate that Novogen's NV-128 (a novel mTOR inhibitor), when used in combination with...

Inverness Medical Innovations Inc builds presence in Africa.
October 31, 2008... Inverness Medical Innovations announced that it recently completed the acquisitions of Vision Biotech (Pty) Ltd and Global Diagnostics CC both located in South Africa. Together, these companies reported combined annual revenues of...

Vectura Group plc receives EUR 7.5 M milestone from Boehringer Ingelheim Corp.
October 31, 2008... Vectura Group plc announces that a EUR 7.5 M milestone payment will be received from Boehringer Ingelheim GmbH, under the worldwide collaboration, development and licence agreement with Vectura. Under the terms of the non-exclusive agreement,...

Gene scan of Alzheimer's families identifies four new suspect genes.
October 31, 2008... The first family-based genome-wide association study in Alzheimer's disease has identified the sites of four novel genes that may significantly influence risk for the most common late-onset form of the devastating neurological disorder. In...

An experimental drug for diabetes dispenses insulin in response to glucose levels.
October 31, 2008... An experimental drug for diabetes dispenses insulin in response to glucose levels. Now the biotech company SmartCells, based in Beverly, MA, is developing a drug that may do most of the heavy lifting in controlling diabetes. The injectable...

RPM announces form 4 filings.
October 31, 2008... RPM International Inc announced that restricted stock previously received by the outside directors of the company has vested. The terms of the company's 2003 Restricted Stock Plan for Directors requires the mandatory withholding of that...

Equistar to temporarily idle olefin unit.
October 31, 2008... Equistar Chemicals LP will temporarily idle the olefin unit at La Porte, TX due to declining market and economic conditions. The La Porte olefin unit is expected to remain out of service until early 2009. The plant has a nameplate capacity of...

3SBio Inc announces preliminary 3Q 2008 results.
October 31, 2008... 3SBio Inc announced that it expects to recognize a one-time impairment charge of about RMB Yuan 19 M in 3Q 2008 and affirmed its 2008 full year guidance. For 3Q 2008, 3SBio expects total net revenues of about RMB Yuan 68.2 M, representing an...

Cephalon receives FDA Approval for Treanda to treat patients with relapsed indolent non-Hodgkin's lymphoma.
October 31, 2008... Cephalon Inc announced that the US Food and Drug Administration (FDA) has approved Treanda (bendamustine hydrochloride) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during...

Genesis Pharmaceuticals files counter claims.
October 31, 2008... Genesis Pharmaceuticals Enterprises Inc (Genesis Pharmaceuticals), was granted leave by the American Arbitration Association ("AAA") to amend its counterclaims and add claims for defamation and breach of contract in a contractual dispute with...

Savient submits Biologics Licence Application (BLA) for pegloticase.
October 31, 2008... Savient Pharmaceuticals Inc announced the submission of its BLA to the US Food and Drug Administration (FDA) seeking approval to market pegloticase in the US along with its request for a priority review. Savient's filing includes data from...

Atna reports 3Q 2008 progress at Pinson Gold Project, NV.
October 31, 2008... Atna Resources Ltd (Atna) report activity at the Pinson Gold Mine in Humboldt County, NV. Pinson Mining Co (PMC), a subsidiary of Barrick Gold, spent $5 M on drilling and development activities at Pinson in 3Q 2008 bringing their total...

Apriso granted FDA marketing approval for maintenance of remission of ulcerative colitis.
October 31, 2008... Salix Pharmaceuticals Ltd announced that the US Food and Drug Administration (FDA) has granted marketing approval for Apriso (mesalamine) extended-release capsules 0.375 gm. Apriso is a locally-acting aminosalicylate indicated for the...

Celldex presents results from Phase I studies of CDX-1307 with GM-CSF.
October 31, 2008... Celldex Therapeutics Inc (Celldex) announced initial results from multi-centre Phase I clinical trials of its cancer vaccine candidate, CDX-1307, combined with GM-CSF, at the International Society for the Biologic Therapy of Cancer annual...

Pfizer's Toviaz (fesoterodine fumarate) receives FDA approval for the treatment of overactive bladder.
October 31, 2008... Pfizer Inc said that the US Food and Drug Administration has approved Toviaz (fesoterodine fumarate) extended release tablets for the treatment of overactive bladder (OAB) symptoms. New once-daily Toviaz can significantly reduce the number of...

Anika Therapeutics broadens global distribution for Elevess in four new countries.
October 31, 2008... Anika Therapeutics Inc (Anika) has signed exclusive agreements with three new dermatology focused distributors to market Elevess in Mexico, Chile, Peru and South Korea. Elevess is an injectable filler that reduces the appearance of lines and...

Critical Therapeutics Inc announces stockholder approvals related to merger with Cornerstone BioPharma Holdings Inc and 10-to-1 reverse stock split.
October 31, 2008... Critical Therapeutics Inc announced that its stockholders voted on 31 Oct 2008 to approve the issuance of Critical Therapeutics' common stock pursuant to the Agreement and Plan of Merger, dated as of 1 May 2008, by and among Critical...

Provectus Pharmaceuticals adds fifth centre to Phase II clinical trial of PV-10.
October 31, 2008... Provectus Pharmaceuticals Inc (Provectus) has begun recruitment for its Phase II clinical trial of the company's lead oncology agent PV-10 at a fifth major centre, now covering the northeastern US, in addition to Sydney, Brisbane and...

Neoprobe receives positive response to European RIGS submission.
October 31, 2008... Neoprobe Corp announced that the centralized European Medicines Agency (EMEA) has provided positive formal responses to Neoprobe's scientific advice submission regarding RIGScan CR and the pathway to receive a marketing authorization for the...

Spectrum Pharmaceuticals files supplemental New Drug Application with FDA for Fusilev in colorectal cancer.
October 31, 2008... Spectrum Pharmaceuticals Inc has filed with the FDA the supplemental New Drug Application (NDA) for Fusilev (levoleucovorin) for injection in combination with 5-FU containing regimens in advanced metastatic colorectal cancer. Fusilev is the...

Polyphor to enter into an exclusive agreement with Allergan for the development of Protein Epitope Mimetics (PEM) inhibitors for ophthalmology.
October 31, 2008... Polyphor Ltd has entered into an exclusive worldwide discovery and licence agreement with Allergan Inc, under which Allergan obtains the rights to develop Protein Epitope Mimetics (PEM) cytokine inhibitors for the treatment of conditions and...

Orexo and ProStrakan advance date for taking over rights for Rapinyl in North America.
October 31, 2008... Orexo is changing partner for Rapinyl in North America to ProStrakan. Orexo and the former partner Endo Pharmaceuticals have now set the date for the takeover at 31 Oct 2008. In conjunction with the takeover, Orexo will receive $75,000 from...

Freedom Environmental Services Inc (FESI) executes letter of intent to purchase 30 M gallon biofuel producer with full production revenues estimated at $120 M/y.
October 31, 2008... Freedom Environmental Services Inc (FESI) announced the execution of a letter of intent to purchase a leading biofuel producer having operations in Florida and Pennsylvania. The acquisition target has a fuel production capacity of 30 M...

Trinity Biotech announces 3Q 2008 results; revenues increase to $35.6 M; operating profit increases 56%.
October 31, 2008... Trinity Biotech plc announced results for 3Q and nine months ended Sep 2008. Revenues for 3Q 2008 amounted to $35.6 M ($33.7 M in 3Q 2007). Clinical Laboratory revenues increased by 4.3%, whilst Point of Care revenues increased by 12.4% for...

Cytokinetics Inc reports 3Q 2008 financial results. [2 tables in original article].
October 31, 2008... Cytokinetics Inc reported revenues from research and development collaborations of $3.1 M for 3Q ended Sep 2008. The net loss for 3Q 2008, which included $2.5 M in restructuring charges, was $16.3 M or $0.33/share (net loss of $11.3 M or...

China XLX reports 3Q and nine months of 2008 financial results. [4 tables in original article].
October 31, 2008... China XLX Fertiliser Ltd (China XLX) announced its unaudited financial results for 3Q and nine months ended Sep 2008. Revenue for nine months of 2008 increased by 42.7% to RMB Yuan 1620.5 M (RMB Yuan 1135.4 M for nine months of 2007) due to...

Sanofi-aventis 3Q 2008 adjusted EPS excluding selected items: 3Q 2008 at EUR 1.47, up 5%. [21 tables in original article].
October 31, 2008... Sanofi-aventis reported results for 3Q and nine months of 2008. Consolidated net income for the first nine months of 2008 was EUR 3669 M (consolidated net income of EUR 4510 M for the first nine months of 2007). Sanofi-aventis generated 3Q...

BioCryst reports 3Q 2008 financial results and provides corporate update.
October 31, 2008... BioCryst Pharmaceuticals Inc (BioCryst) announced financial results for 3Q and the nine months ended Sep 2008. For 3Q 2008, the company reported collaborative and other research and development revenues of $8.9 M ($20.5 M in 3Q 2007). This...

Sartorius Stedim Biotech Group: Nine-month report Jan to Sep 2008. [7 tables in original article].
October 31, 2008... Sartorius Stedim Biotech Group reported results for Jan to Sep 2008. At EUR 275 M, sales revenue for the Group at the current exchange rates is 2.4% below the pro forma year-earlier figure of EUR 281.8 M. EBITA (earnings before interest,...

Ziopharm Oncology reports 3Q 2008 financial results.
October 31, 2008... Ziopharm Oncology Inc announced its financial results for 3Q and nine months ending Sep 2008. The company reported a lower net loss for 3Q 2008 of $5.5 M or $0.26/share (net loss for 3Q 2007 of $7.3 M or $0.35/share). The company reported a...

La Jolla Pharmaceutical Co reports 3Q and year-to-date 2008 financial results. [2 tables in original article].
October 31, 2008... La Jolla Pharmaceutical Co reported a net loss for 3Q ended Sep 2008 of $17.1 M or $0.31/share (net loss of $13.3 M or $0.34/share for 3Q ended Sep 2007). The company reported a net loss for nine months ended Sep 2008 of $45.7 M or...

Inspire reports 3Q 2008 financial results. [2 tables in original article].
October 31, 2008... Inspire Pharmaceuticals Inc announced financial results for 3Q ended Sep 2008 reporting a net loss of $9.6 M or $0.17/share. Total revenue for 3Q 2008 was $20 M ($12.2 M for 3Q 2007). Revenue from AzaSite (azithromycin ophthalmic solution)...

Ore Pharmaceuticals announces its continuing transformation into a drug development company - 3Q 2008 financial results reported. [2 tables in original article].
October 31, 2008... Ore Pharmaceuticals Inc (Ore) reported financial results for the 3Q and nine month ended Sep 2008 and strategic update and quarterly highlights. Revenue for 3Q 2008, was $0.2 M (-$0.6 M less than $0.841 M for 3Q 2007, as a result of the...

Chevron Reports 3Q 2008 net income of $7.9 bn, up from $3.7 bn in 3Q 2007. [12 tables in original article].
October 31, 2008... Chevron Corporation (Chevron) reported net income of $7.9 bn or $3.85/ diluted share for the 3Q ended 30 Sep 2008 ($3.7 bn or $1.75/diluted share in 3Q 2007). For the nine months of 2008, net income was $19 bn or $9.23/diluted share ($13.8 bn...

KBR announces 3Q 2008 result. [7 tables in original article].
October 31, 2008... KBR announced that 3Q ended 30 Sep 2008 income from continuing operations was $74 M, or $0.44/diluted share, which included a negative impact of approximately $0.04 to $0.05/diluted share, related to Hurricane Ike (income from continuing...

Nickel producers react to price fall.
October 31, 2008... Australian nickel producers Mincor Resources NL, Mirabele Nickel Ltd, and Albidon Ltd feel that the turbulence on financial markets and the drop in the price of the metal, is forcing them to change strategy. Thus, Mincor has cut its...

Dangote Group invests in cement sector.
October 31, 2008... Nigerian group Aliko Dangote is to invest $250 M in the Ethiopian cement sector. A new plant will be erected in the Oromia region and will be the largest in the country. Production capacity will be 2.5 M tonnes.

German authorities investigate Danisco sale of Danisco Sugar.
October 31, 2008... The German competition authorities are to investigate Nordzucker's acquisition of Danisco Sugar because of concerns over the impact on competition. The DKR 5.6 bn transaction took place in Jul 2008.

FLSmidth wins DKR 260 M order from Copper Mountain Mining.
October 31, 2008... FLSmidth has won a DKR 260 M contract to supply Copper Mountain Mining Corp, Canada, with equipment for an open-cast copper mine near Princeton, BC. FLSmidth will provide detailed engineering work and construction as well as quality assurance...

Novozymes results up in 1-3Q 2008: forecast for 2008 increased.
October 31, 2008... In 1-3Q 2008 Novozymes, Denmark, recorded a result of DKR 1134 M from primary operations, 6% up on 1-3Q 2007. Sales were up 16% to DKR 6121 M. The company has raised its forecast for results from primary operations for the whole of 2008 from...

Surge in profits for Acino in Jan-Sep 2008.
October 31, 2008... Swiss company Acino, a supplier to the pharmaceuticals industry (formerly Schweizerhall) achieved a rise in net profit to SFR 33.9 M in Jan-Sep 2008 (SFR 16.9 M in Jan-Sep 2007). The company now predicts a 35% rise in turnover for 2008.

BASF prepares for a downturn in the economy.
October 31, 2008... German chemicals group BASF aims to cut costs by EUR 1 bn with around 500 different projects by 2012. These projects include the tightening of procuring and sales processes as well as the reorganisation of BASF's 9 largest production...

Continental to cut jobs.
October 31, 2008... The downturn in the automotive industry is having a significant effect on German Continental Group, a supplier to the automotive industry. Profits decreased from EUR 252 M in 3Q 2007 to almost zero in 3Q 2008. The operating result decreased...

"Borealis' Daplen inside" for new Skoda Fabia.
October 31, 2008... On 31 Oct 2008, Borealis AG, a leading provider of innovative, value creating plastics solutions, is helping Volkswagen Group (VW) raise the interior quality and visual appeal of its Skoda Fabia Roomster generation. High-performance Daplen...

Delay for Wega Mining in Burkina Faso: NKR 300 M share issue.
October 31, 2008... Wega Mining ASA, Norway, has received indications of possible delays because of costs going $38 M over budget for the Inata project in Burkina Faso. The excess includes administration and project costs up to commissioning which is scheduled...

Wega Mining reports NKR 52.4 M loss in 3Q 2008.
October 31, 2008... In 3Q 2008 Wega Mining, Norway, reported a pretax loss of NKR 52.4 M, compared with a loss of NKR 79.5 M in 3Q 2007. An operating loss of NKR 65.2 M was recorded for 3Q 2008, compared with a loss of NKR 29.5 M for 3Q 2007.

The week ahead in the European Parliament 3-7 Nov 2008: pesticides.
October 31, 2008... On 4-6 Nov 2008, the committee on the environment, public health, and food safety of the European Parliament was due to adopt a draft recommendation for the second reading of a framework directive on the sustainable use of pesticides.

The week ahead in the European Parliament 3-7 Nov 2008: plant protection products.
October 31, 2008... On 4-6 Nov 2008, the committee on the environment, public health, and food safety of the European Parliament was due to adopt a draft recommendation for a second reading of a regulation relating to the launch onto the market of plant...

The week ahead in the European Parliament 3-7 Nov 2008: cosmetics.
October 31, 2008... On 4-6 Nov 2008, the committee on the environment, public health, and food safety of the European Parliament was expected to adopt, at the first reading stage, a draft report on a recast version of a regulation on cosmetic products.

Notice of merger with the wholly-owned subsidiaries Asahi Glass Urethane Co Ltd and Asahi-Penn Chemical Co Ltd.
October 31, 2008... On 31 Oct 2008, Asahi Glass Co Ltd announced that at the Board of Directors meeting held on Oct 31 2008, Asahi Glass Co Ltd (the company) made a resolution that the company would merge with its wholly-owned consolidated subsidiaries Asahi...

Kaneka: Quarterly financial results for 2Q 2008, ended 30 Sep 2008: Consolidated business performance (cumulative).
October 31, 2008... For its 1H 2008 (period ends 30 Sep 2008), Kaneka Corp has reported net sales of Yen 248.9 bn (Yen 251.1 bn for its 1H 2007), operating income of Yen 10.1 bn (Yen 18.2 bn), ordinary income of Yen 10.2 bn (Yen 18.0 bn), net income of Yen 4953...

Kaneka: Quarterly financial results for 2Q 2008, ended 30 Sep 2008: Chemicals.
October 31, 2008... For its 1H 2008 (period ends 30 Sep 2008), the Chemicals segment of Kaneka Corp has reported net sales of Yen 52.3 bn (Yen 52.0 bn for its 1H 2007) and operating income of Yen 1802 M (Yen 2614 M). The main products of this segment are: PVC...

Kaneka: Quarterly financial results for 2Q 2008, ended 30 Sep 2008: Functional Plastics.
October 31, 2008... For its 1H 2008 (period ends 30 Sep 2008), the Functional Plastics segment of Kaneka Corp has reported net sales of Yen 42.0 bn (Yen 44.2bn for its 1H 2007) and operating income of Yen 3680 M (Yen 6935 M). The main products of this segment...

Kaneka: Quarterly financial results for 2Q 2008, ended 30 Sep 2008: Expandable Plastics and Products.
October 31, 2008... For its 1H 2008 (period ends 30 Sep 2008), the Expandable Plastics and Products segment of Kaneka Corp has reported net sales of Yen 38.1 bn (Yen 37.1 bn for its 1H 2007) and an operating loss of Yen 121 M (operating loss of Yen 1264 M). The...

Kaneka: Quarterly financial results for 2Q 2008, ended 30 Sep 2008: Foodstuffs Products.
October 31, 2008... For its 1H 2008 (period ends 30 Sep 2008), the Foodstuffs Products segment of Kaneka Corp has reported net sales of Yen 61.5 bn (Yen 57.2 bn for its 1H 2007) and operating income of Yen 906 M (Yen 883 M). The main products of this segment...

Kaneka: Quarterly financial results for 2Q 2008, ended 30 Sep 2008: Life Science Products.
October 31, 2008... For its 1H 2008 (period ends 30 Sep 2008), the Life Science Products segment of Kaneka Corp has reported net sales of Yen 20.6 bn (Yen 17.5 bn for its 1H 2007) and operating income of Yen 3355 M (Yen 2302 M). The main products of this segment...

Kaneka: Quarterly financial results for 2Q 2008, ended 30 Sep 2008: Electronics Products.
October 31, 2008... For its 1H 2008 (period ends 30 Sep 2008), the Electronics Products segment of Kaneka Corp has reported net sales of Yen 22.4 bn (Yen 29.1 bn for its 1H 2007) and operating income of Yen 2006 M (Yen 4546 M). The main products of this segment...

Kaneka: Quarterly financial results for 2Q 2008, ended 30 Sep 2008: Synthetic Fibres and Others.
October 31, 2008... For its 1H 2008 (period ends 30 Sep 2008), the Synthetic Fibres and Others segment of Kaneka Corp has reported net sales of Yen 16.7 bn (Yen 18.0 bn for its 1H 2007) and operating income of Yen 1742 M (Yen 3546 M). The main products of this...

Kaneka: Quarterly financial results for 2Q 2008, ended 30 Sep 2008: International sales.
October 31, 2008... For its 1H 2008 (period ends 30 Sep 2008), Kaneka Corp has reported net sales of Yen 248.9 bn (Yen 251.1 bn for its 1H 2007), of which: international sales totalled Yen 91.5 bn (Yen 96.3 bn), and of which: Asia accounted for Yen 33.6 bn (Yen...

Schwarz Pharma presents nine-months 2008 report.
October 31, 2008... The sales trend of the Schwarz Pharma group in the first 9 months of 2008 was in line with the company's expectations and improved year-on-year. The best performing products were Prostavasin (alprostadil), including Edex (alprostadil),...

Evonik to expand Plexiglas business in Russia: jv Destek Ltd to increase extrusion capacity in 2009.
October 31, 2008... Evonik Industries AG and its Russian jv Destek Ltd have decided to nearly triple the existing extrusion capacity at the companies' Podolsk production facility as part of its strategy to develop the Plexiglas business within the Russian...

Honeywell declares quarterly dividend payable on 10 Dec 2008.
October 31, 2008... The Board of Directors of Honeywell International Inc has declared a regular quarterly dividend of $0.275/share on the company's outstanding common stock. The dividend is payable on 10 Dec 2008 to shareowners of record at the close of...

Daiichi Sankyo to dissolve subsidiaries with Sanofi-Aventis.
October 31, 2008... Daiichi Sankyo Co Ltd has announced that the dissolution of its subsidiaries Laboratoire Daiichi Sanofi-aventis (LDS) and Sanofi-aventis Daiichi Pharmaceutical (SDC) have been approved at the board of directors meeting held on 31 Oct 2008....

EU insecticide ruling will hit yields.
October 31, 2008... The Processors and Growers Research Organization maintains that yields and quality of peas and beans would be badly affected if the European Parliament's recommendations to the new EU pesticides approval bill are adopted. The changes endorsed...

Applications of Atlantis 'likely after Christmas.'.
October 31, 2008... Top agronomists in the UK suggest that application of Atlantis (mesosulfuron-methyl plus iodosulfuron-methyl-sodium) to control blackgrass proliferation in wheat is more likely to be made after Christmas rather than before. At this time,...